Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
42,194,093
-
Total 13F shares
-
20,531,051
-
Share change
-
+474,776
-
Total reported value
-
$300,987,054
-
Put/Call ratio
-
0.51%
-
Price per share
-
$14.66
-
Number of holders
-
67
-
Value change
-
+$5,059,618
-
Number of buys
-
34
-
Number of sells
-
31
Institutional Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) as of Q4 2022
As of 31 Dec 2022 Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) had 67 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 20,531,051 shares of stock of the company.
Largest 10 holders included RTW INVESTMENTS, LP, Vivo Capital, LLC, TANG CAPITAL MANAGEMENT LLC, Frazier Life Sciences Management, L.P., Cormorant Asset Management, LP, TimesSquare Capital Management, LLC, BlackRock Inc., DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), PERCEPTIVE ADVISORS LLC, and VANGUARD GROUP INC.
This table shows 67 institutional shareholders of the security as of 31 Dec 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.